Published in final edited form as:

Curr Psychiatry Rep. 2014 December ; 16(12): 513. doi:10.1007/s11920-014-0513-5.

Neuroimaging and Biomarkers in Addiction Treatment

Kathleen A. Garrison and

Department of Psychiatry, Yale University School of Medicine, 1 Church Street, Room 730, New Haven, CT 06510, USA

Marc N. Potenza

Department of Psychiatry, Yale University School of Medicine, 1 Church Street, Room 730, New Haven, CT 06510, USA

Department of Neurobiology and Child Study Center, Yale University School of Medicine, New Haven, CT, USA

Kathleen A. Garrison: kathleen.garrison@yale.edu

Abstract

Neuroimaging studies have made a significant contribution to the efforts to identify measurable indices, or biomarkers, of addictions and their treatments. Biomarkers in addiction treatment are needed to provide targets for treatment, detect treatment subgroups, predict treatment response, and broadly improve outcomes. Neuroimaging is important to biomarkers research as it relates neural circuits to both molecular mechanisms and behavior. A focus of recent efforts in neuroimaging in addiction has been to elucidate the neural correlates associated with dimensions of functioning in substance-use and related disorders, such as cue-reactivity, impulsivity, and cognitive control, among others. These dimensions of functioning have been related to addiction treatment outcomes and relapse, and therefore, a better understanding of these dimensions and their neural correlates may help to identify brain-behavior biomarkers of treatment response. This paper reviews recent neuroimaging studies that report potential biomarkers in addiction treatment related to cuereactivity, impulsivity, and cognitive control, as well as recent advances in neuroimaging that may facilitate efforts to determine reliable biomarkers. This important initial work has begun to identify possible mediators and moderators of treatment response, and multiple promising indices are being tested.

Keywords

Biomarker; Neuroimaging; Addiction; Cue-reactivity; Impulsivity; Cognitive control

© Springer Science+Business Media New York 2014

Correspondence to: Kathleen A. Garrison, kathleen.garrison@yale.edu.

Compliance with Ethics Guidelines

Conflict of Interest Kathleen A. Garrison declares that she has no conflict of interest.

Human and Animal Rights and Informed Consent This article does not contain any studies with human or animal subjects performed by any of the authors.

Introduction

Neuroimaging has helped to elucidate that substance-use disorders are associated with changes in brain structure, function, and neurochemistry. Neuroimaging studies have improved our understanding of the neural correlates of addiction and how these relate to addictive behavior. Nevertheless, the potential impact of neuroimaging on treatment development for addictions has yet to be fully realized. Despite substantial advances, treatments are often not fully effective, and addiction continues to be a major public health burden [1]. Neuroimaging has contributed to our appreciation of the complexity of addiction, highlighting the need for measurable indices, or biomarkers, of addiction to improve treatment outcomes. A “biomarker” typically refers to a measurable indicator of normal or abnormal biological processes or response to treatment [2]. In substance-abuse research, biomarkers are needed to clarify how or why a treatment has an effect, on whom and under what circumstances.

Recent advances in neuroimaging are affording greater opportunities to identify brain biomarkers that might be used to improve outcomes of treatment for substance-use disorders. Neuroimaging is a critical tool in biomarker development because it relates neural circuits to both molecular mechanisms and behavior or clinical variation. In particular, neuroimaging studies are central to an emerging research effort to identify cross-diagnostic processes in substance-use and related disorders based on both behavior and neural circuits [3]. In this work, alterations in brain activation patterns related to dimensions of functioning in individuals with addictions may be considered to represent abnormal processing associated with addictive behavior. Such research holds significant potential for identifying targets for treatment, detecting subgroups for treatment selection, and/or predicting treatment response [4]. As disorder heterogeneity and individual variation pose significant challenges for delivering effective treatment, considering addictions in terms of dimensions of functioning may help to elucidate factors relevant to treatment response and lead to more specific, more effective treatments [4]. This paper reviews neuroimaging research seeking to identify potential biomarkers of treatment response from several dimensions of functioning relevant to addiction: cuereactivity, impulsivity, and cognitive control.

Reactivity to Drug Cues

Enhanced reactivity to drug-related cues is characteristic of substance-use and related disorders, and cue-reactivity is associated with craving and relapse [5]. A better understanding of the neural correlates of cue-reactivity can provide potential brain biomarkers for substance-abuse treatment [6]. In general, functional neuroimaging signals are derived from changes in oxygenated hemoglobin related to local changes in cerebral blood flow and brain metabolism. As such, they provide an indirect measure of neuronal activity and may be used to track the neural correlates of mental activity [7]. Multiple functional neuroimaging studies have used various cue-reactivity paradigms to measure neural responses to drug cues and craving. Newer methods for quantitative coordinate-based meta-analyses of neuroimaging studies, such as activation-likelihood estimation (ALE, [8]), are being used to establish consensus across studies [9, 10, 11–13]. The ALE approach identifies brain regions that show consistent changes in brain activation patterns across

neuroimaging studies, thereby increasing sample size and factoring out effects due to variations in study design. A recent ALE meta-analysis [10•] found convergence across studies of drug (nicotine, alcohol, cocaine, marijuana, and heroin) and non-drug (gambling) cue-reactivity showing increased activity in the amygdala, ventral striatum, and orbitofrontal cortex (OFC), among other regions, suggesting altered processing in these brain regions associated with potentially maladaptive response to cues in addiction. The insula has also been found in several ALE meta-analyses of smoking cue-reactivity [9, 13], including in studies that correlate cue-reactivity to craving [13]. These studies have also begun to distinguish neural cue-reactivity between subgroups such as treatment-seeking and non-treatment-seeking drug users [10•] or nicotine-deprived and non-nicotine-deprived smokers [9].

Multiple functional neuroimaging studies have mapped the relationship between the neural correlates of cue-reactivity and addiction treatment outcomes. This work has shown that cue-reactivity in the limbic cortico-striatal dopamine system is related to craving and relapse [14]. In a recent functional magnetic resonance imaging (fMRI) study, alcohol-dependent individuals showed an increased response to neutral-relaxing cues in the ventromedial prefrontal cortex (vmPFC), anterior cingulate cortex (ACC), ventral striatum, and precuneus, and these activations were associated with higher craving during alcohol or stress cues and a greater likelihood of relapse [15•]. In addition, decreased response in the vmPFC, ACC, precuneus, and insula during stress cue exposure was related to greater relapse severity [15•]. Another recent study [16] found that alcohol-dependent individuals who relapsed showed pre-quit alcohol cue-reactivity-related activation in the medial prefrontal cortex (mPFC) and diminished volumes of the mPFC, OFC, and ACC, whereas abstinent individuals showed increased cue-reactivity-related activation in the midbrain and ventral striatum and increased functional connectivity between the midbrain and amygdala and midbrain and OFC. Another study [17] found that smokers who relapsed showed increased pre-quit cue-reactivity-related activation in the prefrontal cortex (PFC), ACC, insula, and amygdala, as well as reduced functional connectivity between a cue-reactivity network (e.g., insula, amygdala, ACC) and brain regions involved in response inhibition, including the dorsal ACC (dACC) and dorsolateral prefrontal cortex (dlPFC). In that study, smoking cue-reactivity-related activation of the insula and dACC correlated with attentional bias to smoking-related cues, and together, these indices were strongly related to relapse [17]. These and similar studies suggest that neural cue-reactivity, such as dysfunction of the vmPFC, ACC, and related circuits, may represent indicators of substance-abuse relapse [6]. As more studies are conducted, it will be useful to establish consensus on the specific neural correlates of cue-reactivity related to treatment outcomes. An ALE meta-analysis of treatment effects has been attempted [12], but was limited by the small number of studies and by studies reporting correlations only with specific brain regions of interest.

New approaches in neuroimaging are contributing to potential systems-level biomarkers of cue-reactivity and craving. Supervised machine learning or pattern-analysis methods are being used to better define the neural circuits of craving at the level of the individual [18], which may lead to the identification of reliable indicators of treatment outcome. Real-time fMRI is being used to investigate brain states in real time [19], including those related to mental representations of addictive behaviors such as the modulation of craving [18]. Real-

time fMRI has also been used to relate with greater temporal specificity subjective experience to objective data [20], and this approach may be used to investigate how first-person experiences such as self-reported craving relate to neural correlates such as those associated with cue-reactivity. Real-time fMRI neurofeedback has also shown potential as a direct clinical neurotherapeutic intervention [21] to target dimensions of functioning in addiction, such as by training smokers to self-regulate their brain activations and craving experiences in response to drug cues [22, 23].

Impulsivity

Impulsivity—making decisions quickly, without forethought or regard for potential consequences [24]—is associated with most forms of drug taking and clinical disorders including substance abuse and addiction, attention deficit hyperactivity disorder (ADHD), personality disorders, and others [25]. Impulsivity is a multifaceted construct; multiple domains or dimensions are typically identified, with two such domains often identified being impulsive choice/decision-making and impulsive action or rapid response disinhibition [26]. Impulsivity has been associated with poorer addiction treatment outcomes [27, 28]; thus, a better understanding of the neural correlates of impulsivity and its different dimensions may lead to the identification of brain biomarkers related to treatment response. In neuroimaging studies, the neural correlates of impulsivity have been assessed using magnetic resonance imaging (MRI) to correlate individual variations in impulsivity with volumetric measures of specific brain structures; positron emission tomography (PET) to characterize impulsivity-related neurochemistry; and fMRI to measure brain activation patterns during impulsive behaviors such as poor response inhibition, steep temporal discounting, and disadvantageous decision-making [29–31]. From such studies, neurobiological models of impulsivity have been proposed to include networks of brain regions involving the OFC, ACC, vmPFC, and ventral striatum (among other regions), with key roles for dopamine and serotonin (among other neurotransmitters) [24].

Reduced dopamine function in the striatum has been associated with decreased metabolism in prefrontal regions implicated in impulsivity including the OFC and ACC, and impaired dopaminergic modulation of these prefrontal regions has been postulated to underlie impulsive drug taking in addiction [32]. One approach to testing whether the neural correlates of impulsivity relate to treatment outcomes has been to assess dopamine function (receptor availability and displacement) in the striatum. A recent PET study [33] found that lower pretreatment dopamine transmission in the limbic striatum of cocaine-addicted individuals was associated with poorer treatment outcomes, although the behavioral treatment did not change dopamine transmission in treatment responders. Along similar lines, low pretreatment striatal dopamine function was prospectively related to relapse in methamphetamine-addicted individuals [34]. Both studies used raclopride and focused on D2/D3 receptors in the striatum. Although these striatal receptors have been linked to addictions in preclinical and clinical studies of drug addictions and have been related to impulsivity [35], a broader range of studies involving other brain regions and other neurotransmitter systems is needed to identify neurochemical and neural targets for treatment development. Another approach has been to use fMRI to test whether alterations in the neural correlates of reward processing, a central component of addictions that has

been related to impulsivity, are related to treatment response. Two recent small fMRI studies have found that heightened pretreatment reward response in the ventral striatum relates prospectively to relapse in treatment for cocaine [36] and cannabis [37] use disorders. These findings suggest the need for larger longitudinal studies in which neuroimaging measures of reward processing, impulsive behavior, and other factors are examined with respect to treatment outcomes.

Neuroimaging studies are also helping to elucidate the mechanisms by which dimensions of function such as impulsivity may moderate the effects of behavioral and pharmacological treatments in substance-use and related disorders [28]. For example, in alcohol-dependent individuals, poorer response inhibition prior to treatment with modafinil, a cognitive enhancer, was associated with better outcomes [e.g., 38], indicating that modafinil may only be a useful treatment for alcohol in individuals with greater impulsivity. Modafinil has been found to improve response inhibition in alcohol-dependent individuals by influencing activations in brain regions involved in successful inhibition, including the thalamus and supplementary motor area, but only in those with poor initial response inhibition [39]. These and similar studies are generating preliminary data that impulsivity and the related neural correlates may relate importantly to treatment outcomes in addiction.

Cognitive Control

Most forms of substance abuse and addiction are associated with impairments in cognitive control—broadly defined as goal-directed guidance of information processing and behavior [40]—including deficits in response inhibition, cognitive flexibility, working memory, and attention, among others [27]. Cognitive deficits have been associated with poorer treatment retention and, in some cases, poorer outcomes in addiction treatment [41]. Cognitive deficits are therefore relevant to determining potential indices of treatment response. Brain regions implicated in cognitive control include the ACC for conflict monitoring, dlPFC for conflict resolution, right inferior frontal gyrus (IFG) for inhibitory control, and regions in the midbrain and striatum for reward-related learning [42]. Neuroimaging studies indicate that drug-addicted individuals show altered function [e.g., 43], structure [e.g., 44], and connectivity [e.g., 45] across these brain regions and that these changes are associated with cognitive deficits.

Few neuroimaging studies have directly tested whether the neural correlates of cognitive control are related to treatment outcomes and relapse [42, 46; reviews]. Several of these have measured error processing, a critical component of cognitive control that is disrupted in substance-use and related disorders [42]. A recent fMRI study found that reduced activity in the dACC during error processing related prospectively to cocaine relapse and earlier time to relapse, as did activity in the thalamus and left insula in females and males, respectively [47•]. Another recent study found that reduced baseline error-related negativity, an electrophysiological index of cognitive control in electroencephalography (EEG), was associated with cocaine use after treatment [48]. These studies suggest that reduced brain activity related to error processing may be a marker of relapse risk [46].

Other studies have tested the Stroop color-word interference task [49] to determine how cognitive control deficits are related to treatment response. fMRI Stroop is associated with activation of the dACC, dlPFC, insula, striatum, and thalamus [50]. A behavioral intervention for substance-use disorders resulted in improved Stroop performance and lower task-related activations in the ACC, dlPFC, rIFG, and midbrain [51]. Although no relation to treatment response was reported, in earlier studies, Stroop-related activations have been associated with treatment outcomes [e.g., 52]. In a more recent study [53], adolescent smokers with greater pretreatment Stroop-related activity in the ACC, IFG, insula, and thalamus showed a greater reduction in smoking with a behavioral intervention. In a study of pathological gamblers [50], lower pretreatment Stroop-related activity in the vmPFC, ventral striatum, and other brain regions correlated with improved outcomes from a behavioral intervention. Given the small sample sizes in these studies, more work is needed to test the relationship between the neural correlates associated with individual differences in cognitive control and treatment outcomes.

There is evidence that addressing cognitive deficits may improve treatment outcome. Behavioral and pharmacological therapies targeting cognitive functioning have shown promise in the treatment of substance-use and related disorders [41]. Short-term treatment of nicotine dependence with varenicline has been associated with increased working-memory-related activations in the dACC/mPFC and dlPFC and the activations correlated with improved task performance in heavy smokers [54]. Modafinil has been found to boost learning in methamphetamine-addicted individuals and increase task-related activations in the ACC, IFG, and insula [55]. The stimulant methylphenidate has been found to improve performance on cognitive tasks in cocaine-dependent individuals and increase task-related activations in the ACC [56], or reduce activations in the vmPFC [57], suggesting greater task-related engagement. Galantamine treatment has been found to improve sustained attention in abstinent chronic cocaine users [58], and a recent pilot study suggests the possible efficacy of galantamine in reducing cocaine use [59]. These pharmacotherapies offer brain-behavior enhancement that may have clinical utility by targeting cognitive control dimensions in addiction treatment [41], and more studies are warranted to investigate this possibility.

Resting-State Networks

Resting-state functional connectivity has potential to provide systems-level biomarkers of addictions and their treatment. Spontaneous, correlated fluctuations in brain activity at rest, as measured by resting-state fMRI, represent functional brain networks, and alterations in these networks may underlie addictive processes. Studies have related resting-state functional connectivity to genetic, neural, and behavioral measures of cue-reactivity [60], impulsivity [61], and cognitive control [62], among others [63], and beginning work has related alterations in resting-state functional connectivity to treatment outcomes in addictions [e.g., 64, 65]. Other studies provide evidence for pharmacological modulation of resting-state networks as a mechanism of drug effects in the treatment of substance-use and related disorders [66•, 67, 68]. In a recent study, the relative strength of resting-state interactions between three major brain networks—salience, default mode, and executive control—was related to craving and cognitive deficits during withdrawal in smokers [69•].

These findings suggest that the salience network may toggle resources between the default-mode and executive-control networks, and abstinence-related craving may bias this coupling toward the default-mode network, such that less suppression of default-mode activity combined with decreased executive control results in cognitive deficits [69•]. These findings were based on a proposed metric, the resource allocation index, which integrates network dynamics and is an example of a potential brain biomarker of addiction to be derived from resting-state data.

Looking forward, the integration of large resting-state functional connectivity datasets (e.g., 1000 Functional Connectomes Project, www.nitrc.org/projects/fcon_1000, as in [70], and Human Connectome Project, www.humanconnectomeproject.org [71–73]) and data sharing (e.g., International Neuroimaging Data-sharing Initiative, http://fcon_1000.projects.nitrc.org/) have enormous potential to elucidate brain connectivity patterns related to addictions and their treatment.

Moderators and Mediators

The extent to which a factor may influence or moderate treatment outcome versus operate through or mediate treatment outcome may be tested with neuroimaging data. Mediation analyses have been used to examine different dimensions of function related to addiction. For example, activity in the ventral striatum has been found to mediate fully the relationship between dlPFC activity and regulation of craving, suggesting that the inverse relationship between dlPFC activity and craving operates through dlPFC effects on ventral striatum [74]. These findings suggest a neural mechanism for the effects of therapies targeting craving. Likewise, hippocampal volume has been found to mediate the relationship between pre-treatment cocaine use and within-treatment cocaine abstinence in cocaine-dependent individuals receiving cognitive behavioral therapy (CBT) [75]. These findings suggest that hippocampal structure (and possibly function, although this possibility warrants direct investigation) may be particularly relevant to the mechanisms by which CBT operates and may represent an important neural target for treatment development for cocaine and possibly other addictions. More generally, neural correlates of dimensions of functioning derived from neuroimaging studies may indicate moderators and mediators of addiction treatment response (Fig. 1).

Limitations

Neuroimaging studies indicate that dimensions of functioning in addiction are multifaceted constructs with multiple dimensions that rely on distinct but overlapping neural mechanisms and show variation across individuals. These factors contribute to considerable complexity in treatment, but should inform the development of more specific and more effective treatments. Moreover, dysfunction in neural circuits may predispose to or represent a consequence of substance use or both [e.g., 76•, 77]. Thus, it is informative to investigate the neural correlates of dimensions of functioning in other disorders that do not share the same pharmacological or neurotoxic effects as drugs (e.g., gambling disorder). Further investigation of the neural factors associated with specific components of addictions will aid in determining which may be most predictive of treatment responses.

The use of neuroimaging to identify biomarkers of treatment outcomes is challenged by limitations of neuroimaging. Reproducibility in neuroimaging is limited by both differences in methods and designs across studies, as well as by heterogeneity in patient groups and differences in substances, treatments, and outcome indicators, among other factors [78]. Another challenge to determining biomarkers from these studies is that findings in neuroimaging are typically derived from group-level analyses that may not hold at the level of the individual. Many of these limitations may be overcome with recent advances in neuroimaging, such as those described in this review. For example, quantitative meta-analyses allow for testing of brain-behavior hypotheses across diverse tasks and groups [8, 79, 80] (with the possible added benefit of better predicting mental states from brain activation patterns [81]). Such efforts should help to determine more precisely the reproducibility and generalizability of findings. Resting-state fMRI enables task-independent measures to characterize the intrinsic functional organization of addicted and non-addicted brains. The use of supervised machine learning provides more information on the whole-brain neural correlates of addictive processes that may be applied at the level of the individual. Nevertheless, large, well-controlled longitudinal studies are needed to determine whether insights from neuroimaging are able to provide reliable brain biomarkers of addictions and their treatment.

Conclusions

Recent technological and computational advances in neuroimaging have the potential to impact significantly the identification of biomarkers of addictions and their treatment. Neuroimaging has been used to better understand the dimensions of functioning—such as cue-reactivity, impulsivity, and cognitive control, among others—relevant to treatment outcomes in addiction. Although brain biomarkers of treatment response have yet to be identified to date, efforts have investigated mediators and moderators of treatment response, and multiple promising indices are being tested. These advances, as well as integration across neuroimaging modalities and other measures, will be important with respect to improving outcomes in addiction.

Acknowledgments

This study was funded by the following grants: National Institute on Drug Abuse (NIDA) grants P50 DA09241, P20 DA027844, and R01 DA035058 and this work was supported by an award from the American Heart Association 14CRP18200010.

Marc N. Potenza has received financial support or compensation for the following: Dr. Potenza has consulted for and advised Boehringer Ingelheim, Lundbeck, Ironwood, Shire, and INSYS; has consulted for Somaxon; has received research support from the National Institutes of Health, Veteran's Administration, Mohegan Sun Casino, the National Center for Responsible Gaming, and Forest Laboratories, Pfizer, Ortho-McNeil, Oy-Control/Biotie, GlaxoSmithKline, and Psyadon pharmaceuticals; has participated in surveys, mailings, or telephone consultations related to drug addiction, impulse control disorders, or other health topics; has consulted for gambling entities, law offices, and the federal public defender's office in issues related to impulse control disorders; provides clinical care in the Connecticut Department of Mental Health and Addiction Services Problem Gambling Services Program; has performed grant reviews for the National Institutes of Health and other agencies; has guest-edited journal sections; has given academic lectures in grand rounds, CME events, and other clinical or scientific venues; and has generated books or book chapters for publishers of mental health texts.

References

Papers of particular interest, published recently, have been highlighted as:

- Of importance

1. Volkow ND, Baler RD, Goldstein RZ. Addiction: pulling at the neural threads of social behaviors. *Neuron*. 2011; 69(4):599–602. [PubMed: 21338873]
2. De Gruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, et al. Considerations in the evaluation of surrogate endpoints in clinical trials. Summary of a National Institutes of Health workshop. *Control Clin Trials*. 2001; 22(5):485–502. [PubMed: 11578783]
3. Cuthbert BN, Insel TR. Toward the future of psychiatric diagnosis: the seven pillars of RDoC. 2013; 11:126.
4. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. *AJ Psychiatry*. 2010; 167(7):748–751.
5. Drummond DC. What does cue-reactivity have to offer clinical research? *Addiction*. 2000; 95(Suppl 2):S129–S144. [PubMed: 11002908]
6. Volkow ND, Baler RD. Brain imaging biomarkers to predict relapse in alcohol addiction. *JAMA Psychiatry*. 2013; 70(7):661–663. [PubMed: 23636789]
7. Lauritzen M. Reading vascular changes in brain imaging: is dendritic calcium the key? *Nat Rev Neurosci*. 2005; 6(1):77–85. [PubMed: 15611729]
8. Laird AR, Fox PM, Price CJ, Glahn DC, Uecker AM, Lancaster JL, et al. ALE meta-analysis: controlling the false discovery rate and performing statistical contrasts. *Hum Brain Mapp*. 2005; 25(1):155–164. [PubMed: 15846811]
9. Engelmann JM, Versace F, Robinson JD, Minnix JA, Lam CY, Cui Y, et al. Neural substrates of smoking cue reactivity: ameta-analysis of fMRI studies. *Neuroimage*. 2012; 60(1):252–262. [PubMed: 22206965]
10. Chase HW, Eickhoff SB, Laird AR, Hogarth L. The neural basis of drug stimulus processing and craving: an activation likelihood estimation meta-analysis. *Biol Psychiatry*. 2011; 70(8):785–793. [PubMed: 21757184] Quantitative meta-analysis providing consensus across neuroimaging studies of cue-reactivity to drug and non-drug addiction-related cues and craving.
11. Kuhn S, Gallinat J. Common biology of craving across legal and illegal drugs—a quantitative meta-analysis of cue-reactivity brain response. *Eur J Neurosci*. 2011; 33(7):1318–1326. [PubMed: 21261758]
12. Schacht JP, Anton RF, Myrick H. Functional neuroimaging studies of alcohol cue reactivity: a quantitative meta-analysis and systematic review. *Addict Biol*. 2013; 18(1):121–133. [PubMed: 22574861]
13. Tang DW, Fellows LK, Small DM, Dagher A. Food and drug cues activate similar brain regions: a meta-analysis of functional MRI studies. *Physiol Behav*. 2012; 106(3):317–324. [PubMed: 22450260]
14. Jasinska AJ, Stein EA, Kaiser J, Naumer MJ, Yalachkov Y. Factors modulating neural reactivity to drug cues in addiction: a survey of human neuroimaging studies. *Neurosci Biobehav Rev*. 2014; 38:1–16. [PubMed: 24211373]
15. Seo D, Lacadie CM, Tuit K, Hong KI, Constable RT, Sinha R. Disrupted ventromedial prefrontal function, alcohol craving, and subsequent relapse risk. *JAMA Psychiatry*. 2013; 70(7):727–739. [PubMed: 23636842] fMRI study reporting a potential brain biomarker of alcohol cue-reactivity prospectively related to treatment relapse.
16. Beck A, Wustenberg T, Genauck A, Wrase J, Schlagenhauf F, Smolka MN, et al. Effect of brain structure, brain function, and brain connectivity on relapse in alcohol-dependent patients. *Arch Gen Psychiatry*. 2012; 69(8):842–852. [PubMed: 22868938]
17. Janes AC, Pizzagalli DA, Richardt S, de Frederick B, Chuzi S, Pachas G, et al. Brain reactivity to smoking cues prior to smoking cessation predicts ability to maintain tobacco abstinence. *Biol Psychiatry*. 2010; 67(8):722–729. [PubMed: 20172508]

18. LaConte SM, King-Casas B, Cinciripini PM, Eagleman DM, Versace F, Chiu PH. Modulating rt-fMRI neurofeedback interfaces via craving and control in chronic smokers. *Neuroimage*. 2009; 47(Supplement 1):S45–S.
19. LaConte SM. Decoding fMRI brain states in real-time. *Neuroimage*. 2011; 56(2):440–454. [PubMed: 20600972]
20. Garrison KA, Scheinost D, Worhunsky PD, Elwafi HM, Thornhill TA, Thompson E, et al. Real-time fMRI links subjective experience with brain activity during focused attention. *Neuroimage*. 2013; 81:110–118. [PubMed: 23684866]
21. Stoeckel LE, Garrison KA, Ghosh S, Wightton P, Hanlon CA, Gilman JM, et al. Optimizing real time fMRI neurofeedback for therapeutic discovery and development. *Neuroimage Clin*. 2014; 5:245–255. [PubMed: 25161891]
22. Canterberry M, Hanlon CA, Hartwell KJ, Li X, Owens M, LeMatty T, et al. Sustained reduction of nicotine craving with real-time neurofeedback: exploring the role of severity of dependence. *Nicotine Tob Res: Off J Soc Res Nicotine Tob*. 2013; 15(12):2120–2124.
23. Hanlon CA, Hartwell KJ, Canterberry M, Li X, Owens M, Lematty T, et al. Reduction of cue-induced craving through realtime neurofeedback in nicotine users: the role of region of interest selection and multiple visits. *Psychiatry Res*. 2013; 213(1):79–81. [PubMed: 23683344]
24. Dalley JW, Everitt BJ, Robbins TW. Impulsivity, compulsivity, and top-down cognitive control. *Neuron*. 2011; 69(4):680–694. [PubMed: 21338879]
25. Robbins T, Curran H, de Wit H. Special issue on impulsivity and compulsivity. *Psychopharmacology (Berl)*. 2012; 219(2):251–252. [PubMed: 22124671]
26. Potenza MN, Sofuoglu M, Carroll KM, Rounsaville BJ. Neuroscience of behavioral and pharmacological treatments for addictions. *Neuron*. 2011; 69(4):695–712. [PubMed: 21338880]
27. Stevens L, Verdejo-Garcia A, Goudriaan AE, Roeyers H, Dom G, Vanderplasschen W. Impulsivity as a vulnerability factor for poor addiction treatment outcomes: a review of neurocognitive findings among individuals with substance use disorders. *J Subst Abuse Treat*. 2014; 47(1):58–72. [PubMed: 24629886]
28. Loree AM, Lundahl LH, Ledgerwood DM. Impulsivity as a predictor of treatment outcome in substance use disorders: review and synthesis. *Drug Alcohol Rev*. 2014
29. Fineberg NA, Chamberlain SR, Goudriaan AE, Stein DJ, Vanderschuren LJ, Gillan CM, et al. New developments in human neurocognition: clinical, genetic, and brain imaging correlates of impulsivity and compulsivity. *CNS Spectrums*. 2014; 19(1):69–89. [PubMed: 24512640]
30. Jupp B, Dalley JW. Behavioral endophenotypes of drug addiction: etiological insights from neuroimaging studies. *Neuropharmacology*. 2014; 76(Pt B):487–497. [PubMed: 23756169]
31. Parvaz MA, Alia-Klein N, Woicik PA, Volkow ND, Goldstein RZ. Neuroimaging for drug addiction and related behaviors. *Rev Neurosci*. 2011; 22(6):609–624. [PubMed: 22117165]
32. Volkow ND, Wang GJ, Fowler JS, Tomasi D, Telang F. Addiction: beyond dopamine reward circuitry. *Proc Natl Acad Sci U S A*. 2011; 108(37):15037–15042. [PubMed: 21402948]
33. Martinez D, Carpenter KM, Liu F, Slifstein M, Broft A, Friedman AC, et al. Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. *AJ Psychiatry*. 2011; 168(6):634–641.
34. Wang GJ, Smith L, Volkow ND, Telang F, Logan J, Tomasi D, et al. Decreased dopamine activity predicts relapse in methamphetamine abusers. *Mol Psychiatry*. 2012; 17(9):918–925. [PubMed: 21747399]
35. Clark L, Stokes PR, Wu K, Michalczuk R, Benecke A, Watson BJ, et al. Striatal dopamine D(2)/D(3) receptor binding in pathological gambling is correlated with mood-related impulsivity. *Neuroimage*. 2012; 63(1):40–46. [PubMed: 22776462]
36. Jia Z, Worhunsky PD, Carroll KM, Rounsaville BJ, Stevens MC, Pearlson GD, et al. An initial study of neural responses to monetary incentives as related to treatment outcome in cocaine dependence. *Biol Psychiatry*. 2011; 70(6):553–560. [PubMed: 21704307]
37. Yip SW, DeVito EE, Kober H, Worhunsky PD, Carroll KM, Potenza MN. Pretreatment measures of brain structure and reward-processing brain function in cannabis dependence: an exploratory study of relationships with abstinence during behavioral treatment. *Drug Alcohol Depend*. 2014; 140:33–41. [PubMed: 24793365]

38. Joos L, Goudriaan AE, Schmaal L, Fransen E, van den Brink W, Sabbe BG, et al. Effect of modafinil on impulsivity and relapse in alcohol dependent patients: a randomized, placebo-controlled trial. *Eur Neuropsychopharmacol*. 2013; 23(8):948–955. [PubMed: 23141152]
39. Schmaal L, Joos L, Koeleman M, Veltman DJ, van den Brink W, Goudriaan AE. Effects of modafinil on neural correlates of response inhibition in alcohol-dependent patients. *Biol Psychiatry*. 2013; 73(3):211–218. [PubMed: 22858150]
40. Carter CS, van Veen V. Anterior cingulate cortex and conflict detection: an update of theory and data. *Cogn Affect Behav Neurosci*. 2007; 7(4):367–379. [PubMed: 18189010]
41. Sofuoglu M, DeVito EE, Waters AJ, Carroll KM. Cognitive enhancement as a treatment for drug addictions. *Neuropharmacology*. 2013; 64:452–463. [PubMed: 22735770]
42. Luijten M, Machielsen MW, Veltman DJ, Hester R, de Haan L, Franken IH. Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people with substance dependence and behavioural addictions. *J Psychiatry Neurosci*. 2014; 39(3):149–169. [PubMed: 24359877]
43. Nestor LJ, Ghahremani DG, Monterosso J, London ED. Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. *Psychiatry Res*. 2011; 194(3):287–295. [PubMed: 22047731]
44. Sorg SF, Taylor MJ, Alhassoon OM, Gongvatana A, Theilmann RJ, Frank LR, et al. Frontal white matter integrity predictors of adult alcohol treatment outcome. *Biol Psychiatry*. 2012; 71(3):262–268. [PubMed: 22047719]
45. Worhunsky PD, Stevens MC, Carroll KM, Rounsaville BJ, Calhoun VD, Pearson GD, et al. Functional brain networks associated with cognitive control, cocaine dependence, and treatment outcome. *Psychol Addict Behav*. 2013; 27(2):477–488. [PubMed: 22775772]
46. Marhe R, Luijten M, Franken IH. The clinical relevance of neurocognitive measures in addiction. *Front Psychiatry*. 2014; 4:185. [PubMed: 24454294]
47. Luo X, Zhang S, Hu S, Bednarski SR, Erdman E, Farr OM, et al. Error processing and gender-shared and -specific neural predictors of relapse in cocaine dependence. *Brain*. 2013; 136(Pt 4):1231–1244. [PubMed: 23485852] fMRI study reporting reduced activity in the dorsal anterior cingulate cortex during error processing that is related prospectively to cocaine relapse and earlier time to relapse.
48. Marhe R, van de Wetering BJ, Franken IH. Error-related brain activity predicts cocaine use after treatment at 3-month follow-up. *Biol Psychiatry*. 2013; 73(8):782–788. [PubMed: 23374638]
49. MacLeod CM. Half a century of research on the Stroop effect: an integrative review. *Psychol Bull*. 1991; 109(2):163–203. [PubMed: 2034749]
50. Potenza MN, Balodis IM, Franco CA, Bullock S, Xu J, Chung T, et al. Neurobiological considerations in understanding behavioral treatments for pathological gambling. *Psychol Addict Behav*. 2013; 27(2):380–392. [PubMed: 23586456]
51. DeVito EE, Worhunsky PD, Carroll KM, Rounsaville BJ, Kober H, Potenza MN. A preliminary study of the neural effects of behavioral therapy for substance use disorders. *Drug Alcohol Depend*. 2012; 122(3):228–235. [PubMed: 22041256]
52. Brewer JA, Worhunsky PD, Carroll KM, Rounsaville BJ, Potenza MN. Pretreatment brain activation during Stroop task is associated with outcomes in cocaine-dependent patients. *Biol Psychiatry*. 2008; 64(11):998–1004. [PubMed: 18635157]
53. Krishnan-Sarin S, Balodis IM, Kober H, Worhunsky PD, Liss T, Xu J, et al. An exploratory pilot study of the relationship between neural correlates of cognitive control and reduction in cigarette use among treatment-seeking adolescent smokers. *Psychol Addict Behav*. 2013; 27(2):526–532. [PubMed: 23586458]
54. Loughhead J, Ray R, Wileyto EP, Ruparel K, Sanborn P, Siegel S, et al. Effects of the alpha4beta2 partial agonist varenicline on brain activity and working memory in abstinent smokers. *Biol Psychiatry*. 2010; 67(8):715–721. [PubMed: 20207347]
55. Ghahremani DG, Tabibnia G, Monterosso J, Helleman G, Poldrack RA, London ED. Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals. *Neuropsychopharmacology*. 2011; 36(5):950–959. [PubMed: 21289606]

56. Goldstein RZ, Woicik PA, Maloney T, Tomasi D, Alia-Klein N, Shan J, et al. Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. *Proc Natl Acad Sci U S A*. 2010; 107(38):16667–16672. [PubMed: 20823246]
57. Li CS, Morgan PT, Matuskey D, Abdelghany O, Luo X, Chang JL, et al. Biological markers of the effects of intravenous methylphenidate on improving inhibitory control in cocaine-dependent patients. *Proc Natl Acad Sci U S A*. 2010; 107(32):14455–14459. [PubMed: 20660731]
58. Sofuoglu M, Waters AJ, Poling J, Carroll KM. Galantamine improves sustained attention in chronic cocaine users. *Exp Clin Psychopharmacol*. 2011; 19(1):11–19. [PubMed: 21341919]
59. Sofuoglu M, Carroll KM. Effects of galantamine on cocaine use in chronic cocaine users. *Am J Addict*. 2011; 20(3):302–303. [PubMed: 21477060]
60. Janes AC, Nickerson LD, Frederick Bde B, Kaufman MJ. Prefrontal and limbic resting state brain network functional connectivity differs between nicotine-dependent smokers and nonsmoking controls. *Drug Alcohol Depend*. 2012; 125(3):252–259. [PubMed: 22459914]
61. Gordon EM, Devaney JM, Bean S, Vaidya CJ. Resting-state striato-frontal functional connectivity is sensitive to DAT1 genotype and predicts executive function. *Cereb Cortex*. 2013
62. Muller VI, Langner R, Cieslik EC, Rottschy C, Eickhoff SB. Interindividual differences in cognitive flexibility: influence of gray matter volume, functional connectivity and trait impulsivity. *Brain Struct Funct*. 2014
63. Sutherland MT, McHugh MJ, Pariyadath V, Stein EA. Resting state functional connectivity in addiction: lessons learned and a road ahead. *Neuroimage*. 2012; 62(4):2281–2295. [PubMed: 22326834]
64. Camchong J, Stenger A, Fein G. Resting-state synchrony during early alcohol abstinence can predict subsequent relapse. *Cereb Cortex*. 2013; 23(9):2086–2099. [PubMed: 22819968]
65. McHugh MJ, Demers CH, Salmeron BJ, Devous SrMD, Stein EA, Adinoff B. Cortico-amygdala coupling as a marker of early relapse risk in cocaine-addicted individuals. *Front Psychiatry*. 2014; 5:16. [PubMed: 24578695]
66. Konova AB, Moeller SJ, Tomasi D, Volkow ND, Goldstein RZ. Effects of methylphenidate on resting-state functional connectivity of the mesocorticolimbic dopamine pathways in cocaine addiction. *JAMA Psychiatry*. 2013; 70(8):857–868. [PubMed: 23803700] Resting state fMRI study of a pharmacological intervention for cocaine addiction demonstrating that changes in functional connectivity may be a potential mechanism of treatment effects.
67. Schmaal L, Goudriaan AE, Joos L, Kruse AM, Dom G, van den Brink W, et al. Modafinil modulates resting-state functional network connectivity and cognitive control in alcohol-dependent patients. *Biol Psychiatry*. 2013; 73(8):789–795. [PubMed: 23399373]
68. Cole DM, Oei NY, Soeter RP, Both S, van Gerven JM, Rombouts SA, et al. Dopamine-dependent architecture of cortico-subcortical network connectivity. *Cereb Cortex*. 2013; 23(7):1509–1516. [PubMed: 22645252]
69. Lerman C, Gu H, Loughhead J, Ruparel K, Yang Y, Stein EA. Large-scale brain network coupling predicts acute nicotine abstinence effects on craving and cognitive function. *JAMA Psychiatry*. 2014; 71(5):523–530. [PubMed: 24622915] Resting state fMRI connectivity study linking an index of large-scale network dynamics to craving and withdrawal during short-term abstinence, with implications for treatment.
70. Laird AR, Eickhoff SB, Rottschy C, Bzdok D, Ray KL, Fox PT. Networks of task co-activations. *Neuroimage*. 2013; 80:505–514. [PubMed: 23631994]
71. Biswal BB, Mennes M, Zuo XN, Gohel S, Kelly C, Smith SM, et al. Toward discovery science of human brain function. *Proc Natl Acad Sci U S A*. 2010; 107(10):4734–4739. [PubMed: 20176931]
72. Craddock RC, Jbabdi S, Yan CG, Vogelstein JT, Castellanos FX, Di Martino A, et al. Imaging human connectomes at the macroscale. *Nat Methods*. 2013; 10(6):524–539. [PubMed: 23722212]
73. Smith SM, Vidaurre D, Beckmann CF, Glasser MF, Jenkinson M, Miller KL, et al. Functional connectomics from resting-state fMRI. *Trends Cogn Sci*. 2013; 17(12):666–682. [PubMed: 24238796]
74. Kober H, Mende-Siedlecki P, Kross EF, Weber J, Mischel W, Hart CL, et al. Prefrontal-striatal pathway underlies cognitive regulation of craving. *Proc Natl Acad Sci U S A*. 2010; 107(33):14811–14816. [PubMed: 20679212]

75. Xu J, Kober H, Wang X, DeVito EE, Carroll KM, Potenza MN. Hippocampal volume mediates the relationship between measures of pre-treatment cocaine use and within-treatment cocaine abstinence. *Drug Alcohol Depend.* In press.
76. Ersche KD, Jones PS, Williams GB, Turton AJ, Robbins TW, Bullmore ET. Abnormal brain structure implicated in stimulant drug addiction. *Science.* 2012; 335(6068):601–604. [PubMed: 22301321] Diffusion tensor imaging study demonstrating common structural abnormalities in brain regions implicated in self-control in drug-addicted individuals and their non-addicted siblings, suggesting a potential neurocognitive endophenotype for drug addiction.
77. Wagner M, Schulze-Rauschenbach S, Petrovsky N, Brinkmeyer J, von der Goltz C, Grunder G, et al. Neurocognitive impairments in non-deprived smokers—results from a population-based multi-center study on smoking-related behavior. *Addict Biol.* 2013; 18(4):752–7561. [PubMed: 22339903]
78. Morgenstern J, Naqvi NH, Debellis R, Breiter HC. The contributions of cognitive neuroscience and neuroimaging to understanding mechanisms of behavior change in addiction. *Psychol Addict Behav.* 2013; 27(2):336–350. [PubMed: 23586452]
79. Robinson JL, Laird AR, Glahn DC, Lovallo WR, Fox PT. Metaanalytic connectivity modeling: delineating the functional connectivity of the human amygdala. *Hum Brain Mapp.* 2010; 31(2): 173–184. [PubMed: 19603407]
80. Yarkoni T, Poldrack RA, Nichols TE, Van Essen DC, Wager TD. Large-scale automated synthesis of human functional neuroimaging data. *Nat Methods.* 2011; 8(8):665–670. [PubMed: 21706013]
81. Wager TD, Lindquist M, Kaplan L. Meta-analysis of functional neuroimaging data: current and future directions. *Soc Cogn Affect Neurosci.* 2007; 2(2):150–158. [PubMed: 18985131]

Potential neuroimaging biomarkers of addiction treatment response

Fig. 1. Schematic diagram describing the role of neural correlates derived from neuroimaging studies as potential biomarkers of addiction treatment response. Brain structure, function, electrophysiology, neurochemistry, and other biological measures related to dimensions of functioning may be indices of mediators or moderators of addiction treatment outcomes